Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
58
HAE Quote, Financials, Valuation and Earnings
Last price:
$80.13
Seasonality move
:
0.35%
Day range:
$79.51 - $80.22
52-week range:
$47.32 - $87.32
Dividend yield:
0%
P/E ratio:
23.34x
P/S ratio:
2.95x
P/B ratio:
4.41x
Volume:
152.7K
Avg. volume:
852.6K
1-year change:
3.36%
Market cap:
$3.7B
Revenue:
$1.4B
EPS (TTM):
$3.43
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HAE
Haemonetics Corp.
|
$311.5M | $1.11 | -4.78% | 68.87% | $90.20 |
|
ABT
Abbott Laboratories
|
$11.4B | $1.30 | 7.51% | -71.7% | $144.43 |
|
BAX
Baxter International, Inc.
|
$2.9B | $0.60 | 2.57% | 118.69% | $23.67 |
|
DXCM
DexCom, Inc.
|
$1.2B | $0.57 | 11.43% | 70.31% | $85.27 |
|
MASI
Masimo Corp.
|
$366.9M | $1.20 | -32.15% | 565.51% | $183.75 |
|
UFPT
UFP Technologies, Inc.
|
$149.6M | $2.17 | 3.47% | 6.38% | $329.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HAE
Haemonetics Corp.
|
$80.01 | $90.20 | $3.7B | 23.34x | $0.00 | 0% | 2.95x |
|
ABT
Abbott Laboratories
|
$124.87 | $144.43 | $217.1B | 15.66x | $0.59 | 1.89% | 4.98x |
|
BAX
Baxter International, Inc.
|
$19.12 | $23.67 | $9.8B | 167.20x | $0.01 | 2.72% | 0.89x |
|
DXCM
DexCom, Inc.
|
$67.42 | $85.27 | $26.3B | 37.52x | $0.00 | 0% | 6.08x |
|
MASI
Masimo Corp.
|
$133.28 | $183.75 | $7.2B | 116.80x | $0.00 | 0% | 4.21x |
|
UFPT
UFP Technologies, Inc.
|
$235.54 | $329.50 | $1.8B | 27.30x | $0.00 | 0% | 3.06x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HAE
Haemonetics Corp.
|
59.05% | 0.217 | 53.75% | 0.93x |
|
ABT
Abbott Laboratories
|
20.25% | 0.426 | 5.99% | 1.12x |
|
BAX
Baxter International, Inc.
|
57.29% | 0.027 | 83.18% | 0.96x |
|
DXCM
DexCom, Inc.
|
48.58% | 1.694 | 9.81% | 1.33x |
|
MASI
Masimo Corp.
|
41.99% | 0.805 | 7.4% | 1.68x |
|
UFPT
UFP Technologies, Inc.
|
29.07% | 2.066 | 10.75% | 1.27x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HAE
Haemonetics Corp.
|
$183.4M | $67.3M | 7.99% | 19.39% | 20.56% | $106.3M |
|
ABT
Abbott Laboratories
|
$5.9B | $2.2B | 22.49% | 29.06% | 19.03% | $2.3B |
|
BAX
Baxter International, Inc.
|
$938M | $194M | -1.9% | -4.83% | 6.84% | $126M |
|
DXCM
DexCom, Inc.
|
$747.4M | $242.5M | 14.67% | 30.94% | 20.05% | $579.4M |
|
MASI
Masimo Corp.
|
$230.6M | $83.7M | -11.41% | -19.18% | 22.53% | $49.7M |
|
UFPT
UFP Technologies, Inc.
|
$42.7M | $23.7M | 11.98% | 18.42% | 15.32% | $32.5M |
Haemonetics Corp. vs. Competitors
-
Which has Higher Returns HAE or ABT?
Abbott Laboratories has a net margin of 11.82% compared to Haemonetics Corp.'s net margin of 14.07%. Haemonetics Corp.'s return on equity of 19.39% beat Abbott Laboratories's return on equity of 29.06%.
Company Gross Margin Earnings Per Share Invested Capital HAEHaemonetics Corp.56.04% $0.81 $2.1B ABTAbbott Laboratories52.05% $0.91 $64.2B -
What do Analysts Say About HAE or ABT?
Haemonetics Corp. has a consensus price target of $90.20, signalling upside risk potential of 12.74%. On the other hand Abbott Laboratories has an analysts' consensus of $144.43 which suggests that it could grow by 15.97%. Given that Abbott Laboratories has higher upside potential than Haemonetics Corp., analysts believe Abbott Laboratories is more attractive than Haemonetics Corp..
Company Buy Ratings Hold Ratings Sell Ratings HAEHaemonetics Corp.3 4 0 ABTAbbott Laboratories15 7 0 -
Is HAE or ABT More Risky?
Haemonetics Corp. has a beta of 0.301, which suggesting that the stock is 69.913% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.716, suggesting its less volatile than the S&P 500 by 28.412%.
-
Which is a Better Dividend Stock HAE or ABT?
Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 1.89% to investors and pays a quarterly dividend of $0.59 per share. Haemonetics Corp. pays -- of its earnings as a dividend. Abbott Laboratories pays out 29.33% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HAE or ABT?
Haemonetics Corp. quarterly revenues are $327.3M, which are smaller than Abbott Laboratories quarterly revenues of $11.4B. Haemonetics Corp.'s net income of $38.7M is lower than Abbott Laboratories's net income of $1.6B. Notably, Haemonetics Corp.'s price-to-earnings ratio is 23.34x while Abbott Laboratories's PE ratio is 15.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 2.95x versus 4.98x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HAEHaemonetics Corp.2.95x 23.34x $327.3M $38.7M ABTAbbott Laboratories4.98x 15.66x $11.4B $1.6B
-
Which has Higher Returns HAE or BAX?
Baxter International, Inc. has a net margin of 11.82% compared to Haemonetics Corp.'s net margin of -1.8%. Haemonetics Corp.'s return on equity of 19.39% beat Baxter International, Inc.'s return on equity of -4.83%.
Company Gross Margin Earnings Per Share Invested Capital HAEHaemonetics Corp.56.04% $0.81 $2.1B BAXBaxter International, Inc.33.09% $0.02 $16.9B -
What do Analysts Say About HAE or BAX?
Haemonetics Corp. has a consensus price target of $90.20, signalling upside risk potential of 12.74%. On the other hand Baxter International, Inc. has an analysts' consensus of $23.67 which suggests that it could grow by 25.02%. Given that Baxter International, Inc. has higher upside potential than Haemonetics Corp., analysts believe Baxter International, Inc. is more attractive than Haemonetics Corp..
Company Buy Ratings Hold Ratings Sell Ratings HAEHaemonetics Corp.3 4 0 BAXBaxter International, Inc.2 13 1 -
Is HAE or BAX More Risky?
Haemonetics Corp. has a beta of 0.301, which suggesting that the stock is 69.913% less volatile than S&P 500. In comparison Baxter International, Inc. has a beta of 0.612, suggesting its less volatile than the S&P 500 by 38.771%.
-
Which is a Better Dividend Stock HAE or BAX?
Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International, Inc. offers a yield of 2.72% to investors and pays a quarterly dividend of $0.01 per share. Haemonetics Corp. pays -- of its earnings as a dividend. Baxter International, Inc. pays out 180.98% of its earnings as a dividend.
-
Which has Better Financial Ratios HAE or BAX?
Haemonetics Corp. quarterly revenues are $327.3M, which are smaller than Baxter International, Inc. quarterly revenues of $2.8B. Haemonetics Corp.'s net income of $38.7M is higher than Baxter International, Inc.'s net income of -$51M. Notably, Haemonetics Corp.'s price-to-earnings ratio is 23.34x while Baxter International, Inc.'s PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 2.95x versus 0.89x for Baxter International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HAEHaemonetics Corp.2.95x 23.34x $327.3M $38.7M BAXBaxter International, Inc.0.89x 167.20x $2.8B -$51M
-
Which has Higher Returns HAE or DXCM?
DexCom, Inc. has a net margin of 11.82% compared to Haemonetics Corp.'s net margin of 23.47%. Haemonetics Corp.'s return on equity of 19.39% beat DexCom, Inc.'s return on equity of 30.94%.
Company Gross Margin Earnings Per Share Invested Capital HAEHaemonetics Corp.56.04% $0.81 $2.1B DXCMDexCom, Inc.61.8% $0.70 $5.3B -
What do Analysts Say About HAE or DXCM?
Haemonetics Corp. has a consensus price target of $90.20, signalling upside risk potential of 12.74%. On the other hand DexCom, Inc. has an analysts' consensus of $85.27 which suggests that it could grow by 26.48%. Given that DexCom, Inc. has higher upside potential than Haemonetics Corp., analysts believe DexCom, Inc. is more attractive than Haemonetics Corp..
Company Buy Ratings Hold Ratings Sell Ratings HAEHaemonetics Corp.3 4 0 DXCMDexCom, Inc.20 4 0 -
Is HAE or DXCM More Risky?
Haemonetics Corp. has a beta of 0.301, which suggesting that the stock is 69.913% less volatile than S&P 500. In comparison DexCom, Inc. has a beta of 1.513, suggesting its more volatile than the S&P 500 by 51.265%.
-
Which is a Better Dividend Stock HAE or DXCM?
Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DexCom, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics Corp. pays -- of its earnings as a dividend. DexCom, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HAE or DXCM?
Haemonetics Corp. quarterly revenues are $327.3M, which are smaller than DexCom, Inc. quarterly revenues of $1.2B. Haemonetics Corp.'s net income of $38.7M is lower than DexCom, Inc.'s net income of $283.8M. Notably, Haemonetics Corp.'s price-to-earnings ratio is 23.34x while DexCom, Inc.'s PE ratio is 37.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 2.95x versus 6.08x for DexCom, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HAEHaemonetics Corp.2.95x 23.34x $327.3M $38.7M DXCMDexCom, Inc.6.08x 37.52x $1.2B $283.8M
-
Which has Higher Returns HAE or MASI?
Masimo Corp. has a net margin of 11.82% compared to Haemonetics Corp.'s net margin of 14.46%. Haemonetics Corp.'s return on equity of 19.39% beat Masimo Corp.'s return on equity of -19.18%.
Company Gross Margin Earnings Per Share Invested Capital HAEHaemonetics Corp.56.04% $0.81 $2.1B MASIMasimo Corp.62.07% -$1.86 $1.4B -
What do Analysts Say About HAE or MASI?
Haemonetics Corp. has a consensus price target of $90.20, signalling upside risk potential of 12.74%. On the other hand Masimo Corp. has an analysts' consensus of $183.75 which suggests that it could grow by 37.87%. Given that Masimo Corp. has higher upside potential than Haemonetics Corp., analysts believe Masimo Corp. is more attractive than Haemonetics Corp..
Company Buy Ratings Hold Ratings Sell Ratings HAEHaemonetics Corp.3 4 0 MASIMasimo Corp.4 3 0 -
Is HAE or MASI More Risky?
Haemonetics Corp. has a beta of 0.301, which suggesting that the stock is 69.913% less volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.208%.
-
Which is a Better Dividend Stock HAE or MASI?
Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics Corp. pays -- of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HAE or MASI?
Haemonetics Corp. quarterly revenues are $327.3M, which are smaller than Masimo Corp. quarterly revenues of $371.5M. Haemonetics Corp.'s net income of $38.7M is lower than Masimo Corp.'s net income of $53.7M. Notably, Haemonetics Corp.'s price-to-earnings ratio is 23.34x while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 2.95x versus 4.21x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HAEHaemonetics Corp.2.95x 23.34x $327.3M $38.7M MASIMasimo Corp.4.21x 116.80x $371.5M $53.7M
-
Which has Higher Returns HAE or UFPT?
UFP Technologies, Inc. has a net margin of 11.82% compared to Haemonetics Corp.'s net margin of 10.6%. Haemonetics Corp.'s return on equity of 19.39% beat UFP Technologies, Inc.'s return on equity of 18.42%.
Company Gross Margin Earnings Per Share Invested Capital HAEHaemonetics Corp.56.04% $0.81 $2.1B UFPTUFP Technologies, Inc.27.66% $2.11 $569.4M -
What do Analysts Say About HAE or UFPT?
Haemonetics Corp. has a consensus price target of $90.20, signalling upside risk potential of 12.74%. On the other hand UFP Technologies, Inc. has an analysts' consensus of $329.50 which suggests that it could grow by 39.89%. Given that UFP Technologies, Inc. has higher upside potential than Haemonetics Corp., analysts believe UFP Technologies, Inc. is more attractive than Haemonetics Corp..
Company Buy Ratings Hold Ratings Sell Ratings HAEHaemonetics Corp.3 4 0 UFPTUFP Technologies, Inc.1 2 0 -
Is HAE or UFPT More Risky?
Haemonetics Corp. has a beta of 0.301, which suggesting that the stock is 69.913% less volatile than S&P 500. In comparison UFP Technologies, Inc. has a beta of 1.103, suggesting its more volatile than the S&P 500 by 10.324%.
-
Which is a Better Dividend Stock HAE or UFPT?
Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UFP Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics Corp. pays -- of its earnings as a dividend. UFP Technologies, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HAE or UFPT?
Haemonetics Corp. quarterly revenues are $327.3M, which are larger than UFP Technologies, Inc. quarterly revenues of $154.6M. Haemonetics Corp.'s net income of $38.7M is higher than UFP Technologies, Inc.'s net income of $16.4M. Notably, Haemonetics Corp.'s price-to-earnings ratio is 23.34x while UFP Technologies, Inc.'s PE ratio is 27.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 2.95x versus 3.06x for UFP Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HAEHaemonetics Corp.2.95x 23.34x $327.3M $38.7M UFPTUFP Technologies, Inc.3.06x 27.30x $154.6M $16.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
